Construct Validity of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis

Arthritis Care and Research

Volumn 66, Issue 11, 2014, Pages 1725-1730

  Nagaraja, Vivek ^a   Hays, Ron D ^b   Khanna, Puja P ^a   Spiegel, Brennan M R ^b   Chang, Lin ^b   Melmed, Gil Y ^c   Bolus, Roger ^b   Khanna, Dinesh ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BELLY PAIN; BLOATING; CONSTIPATION; CONSTRUCT VALIDITY; CONTROLLED STUDY; CONVERGENT VALIDITY; CORRELATION ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISCRIMINANT VALIDITY; DYSPHAGIA; EMOTIONAL WELL BEING; FECES INCONTINENCE; FEMALE; FLATULENCE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM GASTROINTESTINAL SYMPTOM SCALE; SCLERODERMA CLINICAL TRIALS CONSORTIUM GASTROINTESTINAL SCALE; SOCIAL INTERACTION; SYSTEMIC SCLEROSIS; VOMITING; WELLBEING;

EID: 84999977031     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22337     Document Type: Article

References (31)

1. Spiegel BM. Patient-reported outcomes in gastroenterology: clinical and research applications. J Neurogastroenterol Motil 2013;19:137–48.
2. Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol 2013;25:700–6.
3. Khanna D, Tsevat J. Health-related quality of life: an introduction. Am J Manag Care 2007; Suppl 9:S218–23.
4. Lock G, Holstege A, Lang B, Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997;92:763–71.
5. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265–82.
6. Bodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, et al. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford) 2011;50:330–4.
7. Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767–76.
8. Bae S, Allanore Y, Furst DE, Bodukam V, Coustet B, Morgaceva O, et al. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol 2013; Suppl 76:57–63.
9. Baron M, Hudson M, Steele R, Lo E, and the Canadian Scleroderma Research Group.Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. J Rheumatol 2011;38:1925–30.
10. Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J Rheumatol 2011;38:1920–4.
11. Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61:1257–63.
12. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; Suppl 1:S3–11.
13. Khanna D, Krishnan E, Dewitt EM, Khanna PP, Spiegel B, Hays RD. The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS). Arthritis Care Res (Hoboken) 2011; Suppl 11:S486–90.
14. Spiegel BM, Khanna D, Bolus R, Agarwal N, Khanna P, Chang L. Understanding gastrointestinal distress: a framework for clinical practice. Am J Gastroenterol 2011;106:380–5.
15. Spiegel BM, Hays RD, Bolus R, Melmed GY, Chang L, Whitman C, et al. Development of the NIH Patient Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 2014. In press.
16. Hays RD, Liu H, Spritzer K, Cella D. Item response theory analyses of physical functioning items in the medical outcomes study. Med Care 2007; Suppl 1:S32–8.
17. Reeve BB, Hays RD, Bjorner JB, Cook KF, Crane PK, Teresi JA, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; Suppl 1:S22–31.
18. Fries JF, Cella D, Rose M, Krishnan E, Bruce B. Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol 2009;36:2061–6.
19. DeWalt DA, Rothrock N, Yount S, Stone AA, Group PC. Evaluation of item candidates: the PROMIS qualitative item review. Med Care 2007; Suppl 1:S12–21.
20. Bae S, Allanore Y, Coustet B, Maranian P, Khanna D. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium gastrointestinal tract instrument. Clin Exp Rheumatol 2011; Suppl 65:S15–21.
21. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90.
22. Nunnally JC.Psychometric theory. 2nd ed.New York:McGraw-Hill; 1978.
23. Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull 1959;56:81–105.
24. Khanna D, Maranian P, Rothrock N, Cella D, Gershon R, Khanna PP, et al. Feasibility and construct validity of PROMIS and “legacy” instruments in an academic scleroderma clinic. Value Health 2012;15:128–34.
25. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Brit J Rheumatol 1989;28:281–6.
26. Frech T, Hays RD, Maranian P, Clements PJ, Furst DE, Khanna D. Prevalence and correlates of sleep disturbance in systemic sclerosis: results from the UCLA scleroderma quality of life study. Rheumatology (Oxford) 2011;50:1280–7.
27. Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 2006;36:173–81.
28. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006;23:691–712.
29. Yarze JC, Varga J, Stampfl D, Castell DO, Jimenez SA. Esophageal function in systemic sclerosis: a prospective evaluation of motility and acid reflux in 36 patients. Am J Gastroenterol 1993;88:870–6.
30. Fries J, Rose M, Krishnan E. The PROMIS of better outcome assessment: responsiveness, floor and ceiling effects, and internet administration. J Rheumatol 2011;38:1759–64.
31. Rose M, Bjorner JB, Becker J, Fries JF, Ware JE. Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol 2008;61:17–33.